Schedule 13G/A
RGNX Schedule 13G/A filing by JPMorgan Chase / Asset Management
JPMorgan Chase / Asset Management reported beneficial ownership of 2.3M shares, representing 12% of REGENXBIO Inc. in this filing.
FiledJun 4, 2026
Ownership dateMay 29, 2026
Reported shares2.3M
Reported ownership12%
Ownership details
Voting and dispositive power reported in the filing
These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.
Sole voting power
2.1M
Shared voting power
2.3M
Sole dispositive power
2.3M
Shared dispositive power
2.3M
Price context
Price dates alongside the ownership filing
Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.
Close near filing date$6.88as of Jun 4, 2026
Latest tracked price$10.50as of Aug 5, 2026
Source
Original filing and accession
Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.
- Reporting filer
- JPMorgan Chase / Asset Management
- CIK
- CIK0000019617
- Accession
- 0000019617-26-000236
- Form
- Schedule 13G/A
Read the filing in context